Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OKs gene therapy trial for Boston and Corautus:

This article was originally published in Clinica

Executive Summary

The US FDA has approved the start of a phase IIB clinical trial of a gene therapy technology for severe cardiovascular disease that is being developed jointly by Corautus Genetics and Boston Scientific. The study will test the efficacy and safety of defined doses of Corautus' angiogenesis-promoting vascular endothelial growth factor-2 (VEGF-2) gene percutaneously delivered via Boston's Stiletto endocardial direct injection catheter. The catheter is modelled to deliver genes to the heart without deactivating them, a problem that, according to Boston, may occur with non-gene specific catheters. The randomised, double-blinded, dose-ranging and placebo-controlled study will involve up to 404 patients with class III or IV angina at around 20 US centres. In July 2003, Atlanta, Georgia-based Corautus entered into a strategic alliance with Boston to develop, commercialise and distribute VEGF-2 gene therapy products.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel